Ligelizumab: A promising option on the horizon for the management of chronic spontaneous urticaria

Chronic spontaneous urticaria may pose challenges for the treatment in some patients. Different options for the management of chronic urticaria include second-generation antihistamines, leukotriene receptor antagonists, omalizumab (anti-IgE antibody), and immunosuppressants. Omalizumab, a monoclonal...

Full description

Bibliographic Details
Main Authors: Kiran Godse, Anant D Patil, Gauri Godse
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2021-01-01
Series:Indian Journal of Drugs in Dermatology
Subjects:
Online Access:http://www.ijdd.in/article.asp?issn=2455-3972;year=2021;volume=7;issue=1;spage=12;epage=14;aulast=Godse